Quick Facts: MTHL Uses

• Supports the management of symptoms associated with certain depressive disorders.
• May contribute to improved patient outcomes when used as an adjunct to standard treatment protocols.
• Is utilized as a nutritional supplement to address folate status in some clinical settings.

---

MTHL (L-methylfolate) is a compound that is used to manage certain indications related to the central nervous system. It may support the improvement of symptoms in adults diagnosed with major depressive disorder when it is administered in conjunction with conventional antidepressant medications. By affecting monoamine synthesis, MTHL is suggested to influence the regulation of mood and cognitive function in individuals who may have suboptimal folate levels or genetic variations that affect folate metabolism. This use is primarily focused on its role as a medical food or prescribed supplement, aiming to enhance the patient's response to primary pharmacotherapy.

The therapeutic application of MTHL is concentrated on supporting overall patient well-being and assisting in the recovery process from depressive episodes, particularly for those who have not achieved an adequate response from initial treatment.

Regulatory References

1. NIH MedlinePlus guidance

Who Can and Cannot Use MTHL (L-Methylfolate)

Official regulatory documentation defines eligibility for MTHL by establishing clear rules for exclusion, conditional use, and age-group limitations. The primary population for use is adults who are receiving concurrent antidepressant therapy for Major Depressive Disorder.

---

Eligibility Scope

Classification	Population/Condition	Restriction Details
Contraindicated	Hypersensitivity	Prohibited in individuals with a known allergy to L-methylfolate or its components.
Contraindicated	Untreated B12 Deficiency	Prohibited due to the risk of masking neurological decline in patients with unmanaged pernicious anemia.
Restricted Use	History of Bipolar Disorder	Caution is required due to the documented risk of potentially precipitating manic episodes.
Not Established	Pediatric Population	Safety and effectiveness for the adjunctive indication have not been established in individuals under 18 years of age.
Acceptable Use	Pregnancy and Lactation	Generally considered acceptable/compatible based on its classification as a folate compound; no absolute prohibition is documented.

---

Official Eligibility Summary

Regulatory documents explicitly state that MTHL is contraindicated in cases of documented hypersensitivity or untreated vitamin B12 deficiency. For the adjunctive use in depression, the safety and effectiveness have not been established in the pediatric population. Use in adults with a history of bipolar disorder is restricted and requires caution, while use during pregnancy and lactation is generally compatible.

Interactions with other medicines and products

MTHL (Metformin Hydrochloride) has officially documented interactions primarily centered on its renal clearance and combined pharmacodynamic effects.

Category	Official Regulatory Statement
Specific interacting medicines	Cimetidine, Dolutegravir, Ranolazine, Furosemide, Carbonic Anhydrase Inhibitors (e.g., Topiramate), Iodinated Contrast Agents
Mechanistic basis	Transporter-mediated clearance modification (inhibition of OCT2), Pharmacodynamic reinforcement (lactic acidosis risk), Impairment of renal function (leading to drug accumulation)
Timing-based rules	MTHL must be temporarily discontinued at the time of or prior to procedures using iodinated contrast agents and withheld for 48 hours afterward, reinstituting only once renal function is confirmed to be normal.

Interaction-Related Restrictions and Classifications

The most stringent classification is the contraindication for use in patients with severely reduced renal function (e.g., estimated eGFR below 30 mL/ min/1.73 m^2). Excessive alcohol intake is formally associated with an increased risk of lactic acidosis and is strongly restricted. Concomitant use with OCT2 inhibitors (e.g., Cimetidine) is documented to increase MTHL plasma concentrations by interfering with its renal tubular secretion, thereby increasing the accumulation risk. Other documented interactions include Furosemide co-administration, which increases MTHL plasma concentration, and a notable long-term effect of MTHL on decreasing Vitamin B12 levels. The regulatory profile advises caution for elderly patients due to the higher likelihood of reduced renal function.

MTHL (Metformin) modulates processes related to systemic glucose concentration through a unique dual-action mechanism centered on regulating cellular energy and signal transduction. Its primary action involves activating the enzyme AMP-activated protein kinase (AMPK), which functions as a central metabolic sensor.

---

Modulating Cellular Energy in the Liver

This domain covers MTHL's initial action as a subtle inhibitor of Mitochondrial Complex I, which triggers a critical increase in the AMP:ATP ratio within liver cells. This change activates AMPK, functionally suppressing the gluconeogenesis pathway and the key enzymes involved, such as PEPCK. The physiological result is a measurable reduction in the liver's endogenous glucose output, leading to a stabilization of the plasma glucose concentration baseline.

---

Enhancing Peripheral Glucose Sensitivity

The second mechanistic domain focuses on MTHL's effects in peripheral tissues like skeletal muscle and fat, where AMPK activation enhances insulin sensitivity. This cascade promotes the translocation of the GLUT4 transporter to the cell surface, which results in increased glucose uptake from the circulation. By enhancing post-receptor signaling, MTHL results in enhanced, non-secretagogue disposal of glucose, which acts in parallel with the reduced output from the liver.

The administration of MTHL (L-Methylfolate Calcium) follows a simplified and consistent routine. The compound is administered via the oral route, primarily supplied as a tablet or capsule dosage form. A standardized daily dosing regimen for adults generally ranges from 7.5 mg to 15 mg. This specific dose, which may be initiated at the lower end of the range, is taken once daily (qDay) to support a sustained therapeutic approach.

There is flexibility regarding intake timing, and MTHL may be taken with or without food. Despite this timing flexibility, the use of MTHL is classified as being under the supervision of a licensed medical practitioner due to its designation as a prescribed medical food. This procedural context underscores the necessity of professional oversight for the initiation and continuation of the compound.

Regarding specific populations, no mandatory dose adjustment is specified for older adults or individuals with existing renal or hepatic impairment within the typical adult range. Conversely, it is noted that the safety and efficacy have not been established for use in pediatric patients. MTHL is intended to serve as part of a long-term therapeutic plan for the dietary management of unique nutritional needs, and the discontinuation of treatment generally does not require a complex dose-tapering procedure. This simple, once-daily protocol defines the approach to using the medicine.

Research Evidence / Overview of Studies for MTHL (L-Methylfolate)

Evidence for Use in Major Depressive Disorder (MDD) as Adjunctive Therapy

The existing research base for MTHL is primarily derived from short-term, randomized, controlled trials (RCTs). These studies were applied in research contexts involving fluctuating or unstable symptoms, focusing on adults with a formal diagnosis of Major Depressive Disorder. Specifically, researchers evaluated individuals who were classified as inadequate responders—meaning they did not achieve sufficient symptom relief—following a full course of standard antidepressant therapy, such as SSRIs or SNRIs. The research examined outcomes related to systemic or functional imbalance by measuring changes in standardized scoring scales used in psychiatric settings.

Studies conducted during periods of heightened symptom activity monitored outcomes reflecting daily functioning or activity level and quantified the number of patients achieving predefined scores for treatment response or remission. Findings describe measurements observed in the studies, where some trials documented the proportion of patients reaching criteria for treatment response compared to those taking an inactive placebo. Findings were mixed across the full range of doses studied. The research monitored a lack of a difference between the compound and placebo when one of the studied doses was compared in some primary controlled trials. This evidence contributes to understanding symptom patterns, but findings describe group patterns, not personal outcomes.

Studies in Specific Patient Subgroups

Studies explored outcomes in specific subgroups defined by characteristics like genetic markers or comorbid conditions (e.g., obesity). These studies monitored outcomes linked to inflammatory or irritative states and genetic profiles that were relevant to the study design. Findings indicate that observed patterns may vary across these small cohorts. The data for these certain groups remain insufficient, and evidence quality varies across studies, meaning that the research provides limited insight into how the compound may interact with all potential patient characteristics.

What Remains Uncertain in the Research

The evidence landscape for MTHL is characterized by several limitations. The certainty remains low because the results apply only to the specific populations studied (i.e., those who had an inadequate response to antidepressants). Follow-up durations were limited, and the core evidence quality varies across studies. A full understanding of sustained outcomes is not yet available. Comparative evidence is lacking; data comparing MTHL to other adjunctive treatments for refractory MDD are insufficient. These research limitations indicate that the data are still emerging, and a complete picture of the compound's role in the broader treatment landscape remains the subject of ongoing research.

Key Studies & References

1. L-methylfolate: MedlinePlus Drug Information

Common questions about MTHL (FAQ)

Q: How does this drug affect my cholesterol levels?

Studies referenced in official product information have examined the effects of this drug on lipid (fat) variables in the blood. These studies reported varied changes in levels of total cholesterol, triglycerides, LDL-cholesterol, and HDL-cholesterol. Official product information notes these findings, but does not provide specific claims about the drug's effect on cholesterol levels in all patients.

---

Q: Can I stop taking the medicine if I feel dizzy or lightheaded?

Official information indicates that dizziness or lightheadedness are symptoms associated with serious, rare side effects, such as lactic acidosis. These symptoms may also be related to other conditions like hypoglycemia (low blood sugar). Symptoms like dizziness or lightheadedness should prompt consultation with a healthcare professional.

---

Q: Does the medication affect my sleep?

Regulatory documents list increased somnolence, which is a state of severe drowsiness, as a symptom associated with the rare but serious adverse effect of lactic acidosis. Somnolence is noted as a symptom that may accompany this serious side effect.

---

Q: Is it safe to crush or chew my tablets to make them easier to swallow?

Official guidance for the extended-release forms of this medication specifies that the tablets must be swallowed whole. They are not designed to be split, crushed, dissolved, or chewed. Official guidance indicates that altering the tablet structure may interfere with the drug's controlled absorption.

---

Q: Is it safe to take ibuprofen (or other NSAIDs) with my medicine?

Regulatory information indicates that taking this medicine alongside nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk of lactic acidosis. Lactic acidosis is a rare but serious side effect. Patient information advises that individuals should review all concurrent medications with a healthcare professional.

---

Q: I forgot to take my pill. What should I do?

Official guidance on a missed dose states that if the next scheduled dose is approaching, the missed dose is typically skipped. If it is not near the time of the next dose, the pill is generally taken as soon as possible. Product information cautions against taking a double dose.

---

Q: Does this drug make me feel tired or fatigued?

Extreme tiredness or fatigue is noted in official regulatory documents as a nonspecific symptom associated with the rare but serious side effect of lactic acidosis. Unusual or severe fatigue is a symptom that should be discussed with a healthcare professional.

---

Q: Is this medicine a generic drug?

Official information confirms that the active ingredient in MTHL is available in generic formulations. Regulatory agencies have approved generic versions of some of the brand-name products containing this active ingredient.

How to Store and Dispose of MTHL

Official Storage Requirements

MTHL (L-methylfolate) must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). The medication must be protected from excessive heat and moisture to preserve its stability.

Regulatory labeling requires the product to be kept in a tightly-closed container in its original packaging. Like all medicines, MTHL must be stored in a secure location and kept out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Unused or expired MTHL should not be disposed of in household trash or by flushing it down the toilet (wastewater). Disposal must be managed through an official drug take-back program or according to local regulations for pharmaceutical waste.